A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC).

Trial Profile

A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jan 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 May 2012 Additional lead trial investigator (Mary F. Mulcahy) identified as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top